Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723994 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT02723994 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 171 participants.
The verdict
NCT02723994, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Ruxolitinib
- DRUG Cytarabine
- DRUG Asparaginase Erwinia Chrysanthemi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723994
The ClinicalTrials.gov registry entry for NCT02723994 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02723994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02723994 about?
NCT02723994 is a clinical study titled "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia". This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will eval...
What is the current status of trial NCT02723994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2016-09-30. Estimated completion is 2026-03-03.
What interventions are being tested in trial NCT02723994?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Ruxolitinib (DRUG), Cytarabine (DRUG), Asparaginase Erwinia Chrysanthemi (DRUG).
Who is sponsoring clinical trial NCT02723994?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.